Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study

Asadi et al., Journal of Pharmaceutical Policy and Practice, doi:10.1186/s40545-023-00511-w
Jan 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 660 hospitalized patients in Iran comparing 6 different drug regimens: 1. HCQ or CQ+AZ, 2. interferons (ReciGen/Ziphron) or interferon + Kaletra (lopinavir/ritonavir), 3. atazanavir, 4. remdesivir, 5. favipiravir, and 6. corticosteroids (dexamethasone/methylprednisolone).
Results show lower risk for HCQ/CQ+AZ in 20 of 25 comparisons (5 outcomes and 5 alternate regimens), with statistical significance in only two cases.
Asadi et al., 16 Jan 2023, retrospective, Iran, peer-reviewed, 7 authors, study period February 2020 - February 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study
Jalal Asadi, Mohammad Aziz Rasouli, Ebrahim Ghaderi, Daem Roshani, Behzad Mohsenpour, Yousef Moradi, Ghobad Moradi
Journal of Pharmaceutical Policy and Practice, doi:10.1186/s40545-023-00511-w
Objectives Different drugs have different effects on the prognosis of patients with COVID-19. This study aimed to evaluate the effect of different drug regimens on patients with COVID-19, hospitalized in Sanandaj city. Methods In this retrospective cohort study, 660 patients with COVID-19, hospitalized in the Tohid, Kowsar and Besat hospitals located Sanandaj (Kurdistan Province, Iran) were studied from February 2020 to February 2021 with clinical symptoms and positive test results. Results The results of multivariate regression analysis showed the days of hospitalization for patients who had received the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) was 1.92 times higher than those who had received the drug regimen 1 (hydroxychloroquine group or a combination of chloroquine and azithromycin) while a significant association was observed (OR = 1.92, 95% CI: 1.16-3.16, P = 0.011). Also, the hospitalization in ICU was longer in patients treated by the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) (OR = 4.63, 95% CI: 1.80-11.82, P = 0.001), however, drug regimens did not show a significant effect on mortality and use of ventilator in patients (P > 0.05). Conclusion The study results showed the drug regimens 2 and 5 increased the days of hospitalization and hospitalization in ICU, respectively, while the other drug regimens had no significant effect on mortality and use a ventilator in the studied patients and none of the drug regimens had an effect on reducing mortality compared to other ones.
Abbreviations HIS Declarations Ethics approval and consent to participate The Ethics Committee of Kurdistan University of Medical Sciences (IR.MUK. REC.1399.316) reviewed and approved this study. (All patients provided written informed consents. The relevant guidelines and regulations performed all methods.) Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress. Learn more Ready to submit your research Ready to submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Adeli, Fesharaki, Evaluation of COVID-19 treatment outcomes in a military hospital and its comparison with a nonmilitary hospital, Journal Mil Med
Almazrou, Almalki, Alanazi, Alqahtani, Alghamd, Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: a retrospective cohort study, Saudi Pharmaceutical Journal
Ansems, Grundeis, Dahms, Mikolajewska, Thieme et al., Remdesivir for the treatment of COVID-19, Cochrane Database Syst Rev, doi:10.1002/14651858.CD014962
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis
Assiri, Iqbal, Mohammed, Alsaleh, Assiri et al., COVID-19 related treatment and outcomes among COVID-19 ICU patients: a retrospective cohort study, J Infect Public Health
Bahl, Johnson, Chen, Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients, Intern Emerg Med
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavirritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Ceylan, Estimation of COVID-19 prevalence in Italy, Spain, and France, Sci Total Environ
Chibber, Haq, Ahmed, Andrabi, Singh, Advances in the possible treatment of COVID-19: a review, Eur J Pharmacol
Cunningham, Goh, Koh, Treatment of COVID-19: old tricks for new challenges, Crit Care, doi:10.1186/s13054-020-2818-6
Felsenstein, Herbert, Mcnamara, Hedrich, COVID-19: immunology and treatment options, Clin Immunol
Garibaldi, Wang, Robinson, Zeger, Bandeen-Roche et al., Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19, JAMA Netw Open
Gautret, Lagier, Parola, Meddeb, Mailhe et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Guner, Hasanoglu, Kayaaslan, Aypak, Akinci et al., Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir, J Infect Public Health
Haider, Gour, Pandey, Kanwar, Tiwari et al., COVID-19 infection: targeting possibilities for treatment. Critical reviews ™ in therapeutic drug carrier systems, Crit Rev Ther Drug Carrier Syst
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep
Ismail, Jamil, Rahman, Bakar, Saad et al., The implementation of Hospital Information System (HIS) in tertiary hospitals in Malaysia: a qualitative study, Malays J Public Health Med
Jean, Lee, Hsueh, Treatment options for COVID-19: the reality and challenges, J Microbiol Immunol Infect
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Keller, Kitsis, Arora, Chen, Agarwal et al., Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19, J Hosp Med
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis
Li, Liao, Zhou, Wang, Yang et al., Comparison of associations between glucocorticoids treatment and mortality in COVID-19 patients and SARS patients: a systematic review and meta-analysis, Shock
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, Med
Nojomi, Yassin, Keyvani, Makiani, Roham et al., Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial, BMC Infect Dis
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Saba, Elsheikh, Forecasting the prevalence of COVID-19 outbreak in Egypt using nonlinear autoregressive artificial neural networks, Process Saf Environ Prot
Somers, Eschenauer, Troost, Golob, Gandhi et al., Tocilizumab for treatment of mechanically ventilated patients with COVID-19, Clin Infect Dis
Stasi, Fallani, Voller, Silvestri, Treatment for COVID-19: An overview, Eur J Pharmacol, doi:10.1016/j.ejphar.2020.173644
Tong, Su, Yu, Wu, Chen et al., Ribavirin therapy for severe COVID-19: a retrospective cohort study, Int J Antimicrob Agents
Vahedi, Ghanei, Ghazvini, Azadi, Izadi et al., The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study, DARU J Pharm Sci
Wani, Clinical profile and outcome of covid positive obstetric patients in a tertiary care hospital-a retrospective study, Online J Health Allied Sci
Wissel, Camp, Kouril, Weis, Glauser et al., An interactive online dashboard for tracking COVID-19 in U.S. counties, cities, and states in real time, J Am Med Inform Assoc
Ye, Wang, Colunga-Lozano, Prasad, Tangamornsuksan et al., Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis, CMAJ
Yu, Salvador, Melani, Berg, Neblett et al., Racial residential segregation and economic disparity jointly exacerbate COVID-19 fatality in large American cities, Ann N Y Acad Sci, doi:10.1111/nyas.14567
Zhong, Wang, Zhang, Liu, Le et al., Efficacy and safety of current therapeutic options for COVID-19-lessons to be learnt from SARS and MERS epidemic: a systematic review and meta-analysis, Pharmacol Res
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop